An investment led by former Morrison & Co chief executive Marko Bogoievski and Sir Stephen Tindall’s investment arm K1W1 into local biotech firm Pictor will see the Kiwis partner with a US laboratory to use its test that allows people to see what kind of antibodies they have in the fight against
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
